Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now later-stage tilt small index

Gender Dysphoria: later-stage trial registry

5 of 9 indexed Gender Dysphoria trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 5 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Gender Dysphoria: 9 US clinical trials tracked, 5 recruiting.

Gender Dysphoria is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is University of Pittsburgh, running 2 of these trials.

Enrollment posture brief

Registry condition gender-dysphoria

OPEN 5 | RECR 56% | LATE 3 | EARLY 1 | RANK #1916 | SPON 2

Nearest open-share peer: Advanced Colorectal Cancer (56% recruiting · 9 trials)

Gender Dysphoria (this)56%Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Gender Dysphoria

Gender Dysphoria lists 5 open slots (56% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Gender Dysphoria on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Gender Dysphoria is recruiting above its size-band peers.

    5 of 9 indexed trials (55.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Gender Dysphoria research.

    University of Pittsburgh accounts for 2 of 9 trials (22.2%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Typical Gender Dysphoria enrolment sits around 90 participants.

    Median target enrolment is 90 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.

  4. Gender Dysphoria splits between interventional and observational designs.

    6 interventional and 3 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 32Phase 41

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 3 640 participants

Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries

Cedars-Sinai Medical Center

NCT04979338

RECRUITING Phase 4 256 participants

Effect of Nitropaste in Chest Masculinizing Surgery

University of Virginia

NCT06428669

RECRUITING 90 participants

Pubertal Blockade and Estradiol Effects on Cardiometabolic Health for Transitioning Youth

University of Colorado, Denver

NCT04596592

RECRUITING NA 78 participants

Evaluating the Efficacy of Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affirming Mastectomy

University of California, San Francisco

NCT07147166

RECRUITING Phase 3 48 participants

Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy

Women and Infants Hospital of Rhode Island

NCT06969326

ACTIVE NOT RECRUITING 150 participants

Testicular Tissue Cryopreservation in the Setting of Gender-Affirming Therapy

University of Pittsburgh

NCT05829928

ACTIVE NOT RECRUITING 20 participants

Ovarian Tissue Cryopreservation in the Setting of Gender-affirming Therapy

University of Pittsburgh

NCT05863676

COMPLETED NA 138 participants

Trans Care: An Online Intervention to Reduce Symptoms of Gender Dysphoria

University of Wisconsin, Madison

NCT05884307

COMPLETED Phase 1 8 participants

Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women

Thomas Jefferson University

NCT04283656

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 3 2
Phase 4 1

Named interventions

Most-linked intervention names on Gender Dysphoria records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Infectious Disease Testing Diagnostic test
2 trials
Trans Care Web App Other
1 trials
Estradiol 2mg Drug
1 trials
Spironolactone 100mg Drug
1 trials
Doravirine/Lamivudine/Tenofovir Drug
1 trials
Gonadal Tissue Removal Procedure
1 trials
Oophorectomy Procedure
1 trials
Nitro-Bid 2 % Topical Ointment Drug
1 trials

US sites by state

Facility locations filed on Gender Dysphoria trials. A trial with sites in several states counts in each.

Pennsylvania 3 trials
California 2 trials
Wisconsin 1 trials
Virginia 1 trials
Rhode Island 1 trials
Colorado 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Gender Dysphoria page

9 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gender Dysphoria condition card totals 9 registered trials; most-linked intervention Infectious Disease Testing; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.